The World Ahead Globe Icon
The World Ahead | The World Ahead 2022

What to expect in year three of the pandemic

New antibody and antiviral treatments, and better vaccines, are on the way

MARBURG, GERMANY - MARCH 29: Employees in special suits test the procedures for the manufacturing of the messenger RNA (mRNA) for the Covid-19 vaccine in German company BioNTech, in Marburg, Germany on March 29, 2021. BioNTech Marburg's coronavirus vaccine production target will be 2.5 billion doses for 2021, up from 2.3 billion as it is considered as one of the largest manufacturing facilities producing mRNA vaccines in the world. The Pfizer-BioNTech vaccine was developed by Ozlem Tureci and Ugur Sahin, a couple who are children of Turkish immigrants in Germany. (Photo by Abdulhamid Hosbas/Anadolu Agency via Getty Images)

By Natasha Loder: Health-policy editor, The Economist

IN THE WELL-VACCINATED wealthier countries of the world, year three of the pandemic will be better than year two, and covid-19 will have much less impact on health and everyday activities. Vaccines have weakened the link between cases and deaths in countries such as Britain and Israel (see chart). But in countries that are poorer, less well vaccinated or both, the deleterious effects of the virus will linger. A disparity of outcomes between rich and poor countries will emerge. The Gates Foundation, one of the world’s largest charities, predicts that average incomes will return to their pre-pandemic levels in 90% of advanced economies, compared with only a third of low- and middle-income economies.

Although the supply of vaccines surged in the last quarter of 2021, many countries will remain under-vaccinated for much of 2022, as a result of distribution difficulties and vaccine hesitancy. This will lead to higher rates of death and illness and weaker economic recoveries. The “last mile” problem of vaccine delivery will become painfully apparent as health workers carry vaccines into the planet’s poorest and most remote places. But complaints about unequal distribution will start to abate during 2022 as access to patients’ arms becomes a larger limiting factor than access to jabs. Indeed, if manufacturers do not scale back vaccine production there will be a glut by the second half of the year, predicts Airfinity, a provider of life-sciences data.

More from The World Ahead

The World Ahead The World Ahead

The World Ahead 2024

Future-gazing analysis, predictions and speculation

The World Ahead The World Ahead

The World Ahead 2024

Future-gazing analysis, predictions and speculation


The World Ahead The World Ahead

The World Ahead 2024

Future-gazing analysis, predictions and speculation